Replies to post #11897 on DNAprint Genomics (DNAG)

[MattG]

Therein lies the problem. What incentive do the drug companies have to include ancestry in thier clinical trials? The drug companies can sell more product if they market to the general population.

Thoughts?

[bag8ger]

Mingwan0,

Thanks for the reminder, I do recall reading that post before.

In addition to trials, I would think private physicians who depend now on self reporting data to make conclusions with respect to treatment, were they to know for sure from test by DNAP, they'd want the patient to get it done.

I think most patients, advised that it would help in their treatment, would want it.

Now, who pays for it. HMOs probably wouldn't, unless it could be shown it would save them money in the long run. Insurance companies probably wouldn't, but maybe would were a good case made for it.

The patient would, those who could afford it. A one time charge, it's less expensive than the prescriptions many of them pay for every month.